12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vigabatrin: Phase IIb data

Top-line data from the double-blind, U.S. Phase IIb CPP-01005 trial in 207 cocaine addicts showed that CPP-109 missed the primary endpoint of a greater proportion of cocaine-free patients during the last 2 weeks of treatment vs. placebo. CPP-109 also missed the secondary endpoints of a greater proportion of cocaine-negative urine tests and a greater reduction in the weekly fraction of cocaine-use days during weeks 3-9 vs. placebo. Catalyst said it expects to complete...

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >